Published in J Mol Recognit on December 01, 1989
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett (1993) 1.47
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol (1996) 1.33
The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol (1991) 1.32
Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther (1991) 1.31
Chemical modification and irreversible inhibition of striatal A2a adenosine receptors. Mol Pharmacol (1992) 1.23
Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). Bioconjug Chem (2009) 1.15
Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett (1990) 1.08
Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. J Recept Res (1992) 0.96
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. J Med Chem (2011) 0.96
Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.94
Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav (1993) 0.93
Adenosine A(2A) receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC. Eur J Pharmacol (2008) 0.87
Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors. Purinergic Signal (2008) 0.87
[(3)H]XAC (xanthine amine congener) is a radioligand for A(2)-adenosine receptors in rabbit striatum. Neurochem Int (1991) 0.85
Fluorescent ligands for adenosine receptors. Bioorg Med Chem Lett (2012) 0.80
Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists. J Nanobiotechnology (2010) 0.79
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A (1980) 5.06
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol (1986) 4.15
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
Purine receptors in mammalian tissues: pharmacology and functional significance. Annu Rev Pharmacol Toxicol (1987) 1.97
The A1 adenosine receptor. Identification of the binding subunit by photoaffinity cross-linking. J Biol Chem (1985) 1.52
Identification of alpha-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding. J Clin Invest (1978) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett (1986) 1.42
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands. J Med Chem (1990) 1.34
Characterization of the A1 adenosine receptor-adenylate cyclase system of cerebral cortex using an agonist photoaffinity ligand. J Neurochem (1986) 1.21
Photoaffinity cross-linked A1 adenosine receptor-binding subunits. Homologous glycoprotein expression by different tissues. J Biol Chem (1986) 1.20
High affinity acylating antagonists for the A1 adenosine receptor: identification of binding subunit. Mol Pharmacol (1988) 1.17
Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem (1989) 1.13
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J Med Chem (1989) 1.13
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor. J Med Chem (1988) 1.09
N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors. J Med Chem (1986) 1.06
Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn Schmiedebergs Arch Pharmacol (1988) 1.06
18F-labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. Biochemistry (1989) 1.03
125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors. J Med Chem (1988) 0.98
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J Med Chem (1987) 0.94
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. J Med Chem (1989) 0.93
Noncompetitive inhibitors reach their binding site in the acetylcholine receptor by two different paths. Mol Pharmacol (1988) 0.79
The sequence of the human genome. Science (2001) 101.55
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood (2000) 9.24
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
A Critical Study of the Methods of Estimating Cholesterol and Allied Substances. Biochem J (1921) 4.58
A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol (1988) 4.41
Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J (2001) 4.40
Lymphocyte trafficking and regional immunity. Adv Immunol (1999) 4.21
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Distribution of NHS funds between fundholding and non-fundholding practices. BMJ (1994) 4.05
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A (1992) 3.91
Enrichment of gene-coding sequences in maize by genome filtration. Science (2003) 3.41
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet (1985) 3.32
Deprivation and cause specific morbidity: evidence from the Somerset and Avon survey of health. BMJ (1996) 3.18
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate. Science (1977) 2.88
Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. J Am Acad Child Adolesc Psychiatry (2001) 2.83
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem (1993) 2.66
Final results from a meta-analysis of remedial interventions with drink/drive offenders. Addiction (1995) 2.66
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med (1997) 2.49
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev (1984) 2.38
Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer (1998) 2.36
Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol (1995) 2.19
Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry (1998) 2.16
Incentive spirometry decreases respiratory complications following major abdominal surgery. Surgeon (2007) 2.15
Possible discrimination in recruitment of psychiatry residents? Am J Psychiatry (1997) 2.14
The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest (1990) 2.12
Prepubertal and young adolescent bipolarity versus ADHD: assessment and validity using the WASH-U-KSADS, CBCL and TRF. J Affect Disord (1998) 2.10
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci (1997) 2.09
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med (2012) 2.05
Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) Hum Mol Genet (1995) 2.02
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1996) 2.02
The segment polarity gene armadillo interacts with the wingless signaling pathway in both embryonic and adult pattern formation. Development (1991) 2.01
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem (1992) 2.01
Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J (2009) 1.99
CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther (1989) 1.99
Purine receptors in mammalian tissues: pharmacology and functional significance. Annu Rev Pharmacol Toxicol (1987) 1.97
Histopathology of the upper small intestines in typhoid fever. Biopsy study of experimental disease in man. Am J Dig Dis (1966) 1.97
Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol (1999) 1.95
Detection of single mammalian cells by high-resolution magnetic resonance imaging. Biophys J (1999) 1.90
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science (1998) 1.87
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 1.86
P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharmacol Exp Ther (2000) 1.85
Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet (1998) 1.83
Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation. Proc Natl Acad Sci U S A (2000) 1.81
Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol (2007) 1.77
Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol (2001) 1.77
Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation (2001) 1.74
Psychosocial functioning in a prepubertal and early adolescent bipolar disorder phenotype. J Am Acad Child Adolesc Psychiatry (2000) 1.74
Peer discussion on training physicians to be competent communicators: support for a multiple discourse approach. South Med J (1997) 1.73
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
A phosphatocopid crustacean with appendages from the Lower Cambrian. Science (2001) 1.70
Adherence by African American men to prostate cancer education and early detection. Cancer (1999) 1.69
P2X7-related modulation of pathological nociception in rats. Neuroscience (2007) 1.67
Liver cells. Methods Enzymol (1979) 1.67
The carbon balance of Africa: synthesis of recent research studies. Philos Trans A Math Phys Eng Sci (2011) 1.65
Sensitivity of Shah, Vanclay and Cooper's modified Barthel Index. Clin Rehabil (1999) 1.62
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
Gene rearrangements in the diagnosis of lymphoma/leukemia. Guidelines for use based on a multiinstitutional study. Am J Clin Pathol (1991) 1.61
Diagnostic characteristics of 93 cases of a prepubertal and early adolescent bipolar disorder phenotype by gender, puberty and comorbid attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol (2000) 1.61
Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther (2000) 1.60
Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfus Med (2012) 1.60
Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry (2001) 1.59
HIV risk behaviors associated with the injection process: multiperson use of drug injection equipment and paraphernalia in injection drug user networks. Subst Use Misuse (1998) 1.58
UK Back pain Exercise And Manipulation (UK BEAM) trial--national randomised trial of physical treatments for back pain in primary care: objectives, design and interventions [ISRCTN32683578]. BMC Health Serv Res (2003) 1.57
One minute wisdom. All you need to know about CS gas. Nurs Stand (1994) 1.55
Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation (2000) 1.55
Autonomic orienting responses in 15-year-old male subjects and criminal behavior at age 24. Am J Psychiatry (1990) 1.54
Sale of sex for drugs and drugs for sex: an economic context of sexual risk behavior for STDs. Sex Transm Dis (1999) 1.53
Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci (1999) 1.53
The A1 adenosine receptor. Identification of the binding subunit by photoaffinity cross-linking. J Biol Chem (1985) 1.52
CT appearances of talc pleurodesis. Clin Radiol (2007) 1.52
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni. J Biol Chem (1987) 1.50
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A (2010) 1.49
Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr (1984) 1.48
The hypronosticon test in breast cancer. Clin Oncol (1975) 1.47
A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A (1993) 1.47
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut (2010) 1.47
Beta 3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin beta 3 subunit. J Cell Biol (1995) 1.46